Navigation Links
Telik Announces Initiation of a Phase 2 Clinical Trial of Telintra® (Ezatiostat HCl) in Patients With Revlimid® Refractory or Resistant Deletion 5q Myelodysplastic Syndrome
Date:6/7/2011

PALO ALTO, Calif., June 7, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today announced the initiation of a Phase 2 clinical trial to evaluate oral Telintra in patients with Revlimid refractory or resistant, deletion 5q myelodysplastic syndrome (del 5q MDS).

This is a multicenter trial intended to enroll up to 117 evaluable patients. It employs a sequential design with two interim analyses. These patients are transfusion dependent with Low to Intermediate-1 Risk MDS. Telintra will be administered for 21 days followed by a one week rest period in four week cycles.  The primary objective is to determine the hematologic improvement-erythroid (HI-E) response rate as measured by transfusion reduction or independence, in accordance with the International Working Group MDS 2006 criteria. Secondary objectives include determination of the hematologic improvement-neutrophil (HI-N) and hematologic improvement-platelet (HI-P) response rates, and safety.  

This trial follows the recently completed Phase 2 study in non-del 5q MDS reported at the 52nd Annual Meeting of the American Society of Hematology 2010 in Orlando, FL, "Phase 2 Randomized Multicenter Study of Extended Dosing Schedules of Oral Ezatiostat HCl (Telintra), a Glutathione Analog, Glutathione-S-transferase P1-1 (GSTP1-1) Inhibitor, In Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)", Raza, A., Galili, N., Smith, S., et al. (Abstract #2910) where evidence of clinical activity was observed in this patient population.  Patients with del 5q MDS have limited treatment options after becoming resistant to Revlimid and represent an important unmet medical need.

Background on MDS and Telintra

The myelodysplastic syndrome is a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis (blood cell production) involving one or more ce
'/>"/>

SOURCE Telik, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Telik Announces Financial Results For 2008 Second Quarter
2. ReceptorBio Announces Diabetes License Agreement With Telik
3. Teliks Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone
4. Telik Announces Receipt of Nasdaq Notice
5. Telik Announces 2008 Third Quarter Financial Release, Conference Call and Webcast
6. Telik Announces Top-Line Results From Assist-5 Trial of Telcyta(R) in Combination With Pegylated Liposomal Doxorubicin in Platinum Refractory and Resistant Ovarian Cancer
7. Telik Announces Financial Results for 2008 Third Quarter
8. Telik Announces New TRAP Drug Discovery Agreement
9. Telik Implements Reorganization to Focus Resources Toward Drug Development Pipeline
10. Telik Reports Preclinical Results at AACR Annual Meeting
11. Telik Announces Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 The Pittcon Organizing Committee ... Food Safety Tech , an e-Journal and producer of ... agreement for the second year for the co-location of Food ... The partnership provides that the registration fee to attend the ...
(Date:1/15/2014)... RedBrick Health , a fast-growing leader in consumer ... EmblemHealth , the New York ... the RedBrick Compass health assessment, combined with the RedBrick ... members. EmblemHealth is among the first health plans in ...
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA theory ... of these latent viruses is the Epstein Barr Virus (EBV), ... arthritis (RA) is a chronic inflammatory disease that destroys the ... that RA patients have high concentrations of EBV DNA in ...
(Date:1/15/2014)... Biotechnology Company, Limited ("TaiGen") today announced that they have ... pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn ® ... Turkey and other members of ... for the treatment of bacterial infections including those caused ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... Inc.,(OTC Bulletin Board: NGNM) announced today that it plans ... July 31, 2008., The Company has scheduled ... results on July 31, 2008, at 11:00 AM EDT. ... 689-8033 (international) at least,five minutes prior to the call. ...
... James C. Powell, former,President and Chief Operating Officer ... of Nerites Corporation., Under Powell,s guidance, SurModics ... partnerships to commercialize products.,Powell joined SurModics in 1987 ... lead the company,s transition from a diagnostics kit,manufacturer ...
... VEGAS, July 29 American Pacific,Corporation (Nasdaq: APFC ... third quarter financial results on Tuesday, August 5, 2008. ... to participate in,a teleconference to review the financial results ... held Tuesday, August 5, 2008 at 1:30 p.m.,PDT. To ...
Cached Biology Technology:NeoGenomics Schedules its Q2 2008 Earnings Release for July 31, 2008 2James C. Powell Joins Nerites Board of Directors 2American Pacific to Release Financial Results and Hold Fiscal 2008 Third Quarter Investor Teleconference 2
(Date:4/17/2014)... about eight years ago, Katia Silvera , a postdoctoral ... were on a field trip in a mountainous area in ... never seen before. , Unable to identify it, they contacted ... turned out to be an unnamed species. So Carnevali recently ... "Lophiaris" is the genus name, comprising about 40 species in ...
(Date:4/17/2014)... a novel method to help kidney stone sufferers ... treatment possible., Kidney stones represent a major medical ... left untreated, apart from being particularly painful, they ... In many patients treated successfully, stone recurrence is ... approach to diagnosis and treatment needs to be ...
(Date:4/17/2014)... expression is the process whereby the genetic information ... such as proteins, which have numerous different functions ... an important intermediary during gene expression, by relating ... mechanisms involved in manufacturing proteins. , By ... molecules present in an organism at a given ...
Breaking Biology News(10 mins):Orchid named after UC Riverside researcher 2Orchid named after UC Riverside researcher 3Rapid and accurate mRNA detection in plant tissues 2
... of £23.6M a year to the UK poultry industry but ... against the disease ?one that can be delivered while they ... vaccine virus which provides immunity to IBV has been developed ... vaccine company Intervet UK. It can be delivered to chicks ...
... simply grab carbon dioxide out of the air and covert ... plants use light as their energy source. Chemists would also ... source for their synthetic reactions, but it doesn’t work just ... Max Planck Institute for Colloids and Interfaces has now taken ...
... of Toronto is revealing biochemical processes responsible for diseases ... the way for pharmaceutical applications. , A study ... describes how U of T and Johns Hopkins University ... play an important role in human health and disease. ...
Cached Biology News:In-shell vaccine for chick disease 2Progress toward artificial photosynthesis? 2Technology reveals 'lock and key' proteins behind diseases 2
Mouse monoclonal [GB3] to Kalinin ( Abpromise for all tested applications). entrezGeneID: 3918 SwissProtID: Q13753...
Rabbit polyclonal to VEZT ( Abpromise for all tested applications). Antigen: Full length human VEZT conjugated to GST Entrez Gene ID: 55591 Swiss Protein ID: Q9HBM0...
AADAC Immunogen: AADAC (NP_001077, 201 a.a. ~ 301 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Mouse monoclonal [CIa] to Ia Antigen (Biotin) ( Abpromise for all tested applications)....
Biology Products: